Clayton, Dubilier & Rice taps Wall Street for $3.1 billion debt package in McKesson carve-out

Clayton, Dubilier & Rice has arranged $3.1 billion in debt financing through a syndicate of Wall Street banks to complete its acquisition of a McKesson Corp. business unit. The financing commitment arrived sixty-seven days after the deal was announced, moving CD&R closer to closing on a healthcare logistics platform that has operated inside McKesson's pharmaceutical distribution apparatus since 2017.

The debt package splits into a $1.8 billion term loan and a $1.3 billion revolving credit facility, both priced at SOFR plus 375 basis points. Six banks anchor the syndicate: JPMorgan Chase, Bank of America, Goldman Sachs, Morgan Stanley, Barclays, and Wells Fargo. The pricing sits 50 basis points tighter than comparable healthcare services LBOs closed in Q4 2024, reflecting either CD&R's negotiating position or structural protections the banks secured in covenant flexibility. McKesson retains a 22 percent equity stake post-close and two board seats, which typically signals confidence in near-term EBITDA stability but also hedges against integration risk the seller wants to monitor.

The financing matters because it marks the first large-scale carve-out LBO in healthcare distribution since CVS Health unwound its specialty pharmacy joint venture in 2022. That transaction failed to meet its year-three revenue targets, and the acquirer wrote down $480 million in goodwill eighteen months after close. CD&R's move now tests whether private equity can extract margin improvement from assets embedded in public-company cost structures without triggering the regulatory scrutiny that has frozen hospital rollups since mid-2023. The McKesson unit generated $640 million in EBITDA over the trailing twelve months, putting the enterprise value at roughly 7.8x EBITTA once you back out the $780 million in cash McKesson is transferring at closing. That multiple compresses to 6.9x if CD&R hits the $90 million in cost synergies it has modeled internally, which hinges on collapsing three regional fulfillment centers into one hub-and-spoke network by month fourteen.

Allocators should track three follow-on events. First, whether the syndicate holds the full $3.1 billion commitment or sells down $600 million to $800 million into the broadly syndicated loan market by April, which would indicate pricing tension beneath the headline terms. Second, whether CD&R raises a co-investment vehicle for the equity layer, which would telegraph that the firm is conserving dry powder for a follow-on healthcare roll-up rather than making this a singular bet. Third, regulatory clearance from the Federal Trade Commission, expected by late February, which could impose divestitures if the combined entity's market share in pharmaceutical logistics exceeds 34 percent in any single state—a threshold three industry attorneys cited in off-record conversations as the enforcement line FTC staff drew in the CVS precedent.

The debt markets priced this deal as if healthcare distribution multiples will hold at current levels through 2026, which assumes no Medicare reimbursement cuts and no margin compression from the three generic drug pricing bills moving through state legislatures. CD&R closed its $26 billion Fund XIII in September and has deployed $4.2 billion across six platform acquisitions since October, a pace that suggests the firm is moving capital ahead of a credit cycle turn it expects by summer.